Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

The University of Chicago

Status: Enrolling

Conditions: Elderly; Prostate Cancer

Treatments: Behavioral: LHRH Agonist Therapy Discontinuation

Study type: Interventional

Funder types: Other

Identifiers

NCT06824818

IRB24-1729

Details and patient eligibility

About

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Enrollment: 155 estimated patients

Sex: Male

Ages: 70+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prostate cancer with >3 years of LHRH agonist therapy.
• Age ≥70 years.
• ECOG performance status ≤2
• Baseline testosterone of < 20 ng/ml
• No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
• Ability to understand and sign informed consent.

Exclusion criteria

• none

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

155 participants in 1 patient group

discontinuation of LHRH agonist therapy in elderly prostate cancer patients

Experimental group

Treatment:

Behavioral: LHRH Agonist Therapy Discontinuation